Press releases
- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
On Thursday, Organon & Co (1OGN:MIL) closed at 19.11, -5.16% below its 52-week high of 20.15, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.11 |
---|---|
High | 19.11 |
Low | 19.11 |
Bid | -- |
Offer | -- |
Previous close | 18.57 |
Average volume | -- |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.08 |
Market cap | 5.32bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.04 EUR |
---|---|
Annual div yield (ADY) | 5.58% |
Div ex-date | Feb 23 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Jun 13 2024 13:36 BST.
More ▼